Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma-Reference-Cited by-同舟云学术

Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma

Published:2018-12-17 Issue:6 Volume:184 Page:999-1005
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Rule Simon¹^ORCID,Cook Gordon²,Russell Nigel H.³,Hunter Ann⁴,Robinson Stephen⁵,Morley Nick⁶,Sureda Anna⁷⁸,Patrick Pip⁹,Clifton-Hadley Laura⁹,Adedayo Toyin⁹,Kirkwood Amy⁹,Peggs Karl S.¹⁰

Affiliation:

1. Plymouth University Medical School; Plymouth UK

2. Leeds Institute of Cancer & Pathology; University of Leeds; Leeds UK

3. Nottingham University Hospital; Nottingham UK

4. Department of Haematology; Leicester Royal Infirmary; Leicester UK

5. Department of Haematology; University Hospitals Bristol; Bristol UK

6. Sheffield Teaching Hospital NHS Foundation Trust; Sheffield UK

7. Haematology Department; Addenbrookes Hospital; Cambridge University Hospitals; Cambridge UK

8. Clinical Hematology Department; Catalan Institute of Oncology; Barcelona Spain

9. Cancer Research UK and University College London Cancer Trials Centre; London UK

10. Department of Haematology; University College London Cancer Institute; London UK

Funder

Cancer Research UK

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.15723/fullpdf

Reference20 articles.

1. Mantle cell lymphoma: evolving management strategies;Campo;Blood,2014

2. Revised Response Criteria for Malignant Lymphoma;Cheson;Journal of Clinical Oncology,2007

3. Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation;Cook;Biology of Blood and Marrow Transplantation,2010

4. Newly diagnosed and relapsed mantle cell lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up;Dreyling;Annals of Oncology,2014

5. 15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau;Eskelund;British Journal of Haematology,2016

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Allogeneic Hematopoietic Stem Cell Transplant;Comprehensive Hematology and Stem Cell Research;2024

2. Diagnosis and management of mantle cell lymphoma: A British Society for Haematology Guideline;British Journal of Haematology;2023-10-25

3. Allogeneic stem cell transplantation achieves long-term remissions in mantle cell lymphoma, including in TP53 -mutated disease;Leukemia & Lymphoma;2023-08-02

4. CAR T-Cell therapy for the management of mantle cell lymphoma;Molecular Cancer;2023-03-31

5. How I manage mantle cell lymphoma: indolent versus aggressive disease;British Journal of Haematology;2023-02-20